Showing results (941-950 of 986) with videos related to
Sort By:
Pageof 99
Lancet (London, England)|July 5, 2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialJean Bennett, Jennifer Wellman, Kathleen A Marshall, et al.Nature|August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Michael Tsabar, Michael S Cuoco, et al.Human Molecular Genetics|August 30, 2014
Mutations in IFT172 cause isolated retinal degeneration and Bardet-Biedl syndromeKinga M Bujakowska, Qi Zhang, Anna M Siemiatkowska, et al.Proceedings of the National Academy of Sciences of the United States of America|May 17, 2017
Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degenerationSheldon Rowan, Shuhong Jiang, Tal Korem, et al.Annals of Medicine and Surgery (2012)|December 28, 2020
Prospective, multicenter study of P4HB (Phasix™) mesh for hernia repair in cohort at risk for complications: 3-Year follow-upJohn Scott Roth, Gary J Anthone, Don J Selzer, et al.JACC. Clinical Electrophysiology|February 28, 2025
Dual- vs Single-Chamber Ventricular Pacing in Isolated Congenital Complete Atrioventricular Block in InfancyReina Bianca Tan, Kristyn A Pierce, James Nielsen, et al.Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.The Journal of Clinical Investigation|October 5, 2013
2-Aminoadipic acid is a biomarker for diabetes riskThomas J Wang, Debby Ngo, Nikolaos Psychogios, et al.Journal of the American College of Surgeons|September 14, 2022
Long-Term, Prospective, Multicenter Study of Poly-4-Hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-UpJohn Scott Roth, Gary J Anthone, Don J Selzer, et al.British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.Pageof 99